PT - JOURNAL ARTICLE AU - Mesha-Gay Brown AU - Cornelia Drees AU - Lidia M Nagae AU - John A Thompson AU - Steven Ojemann AU - Aviva Abosch TI - Curative and palliative MRI-guided laser ablation for drug-resistant epilepsy AID - 10.1136/jnnp-2017-316003 DP - 2017 Oct 30 TA - Journal of Neurology, Neurosurgery & Psychiatry PG - jnnp-2017-316003 4099 - http://jnnp.bmj.com/content/early/2017/10/30/jnnp-2017-316003.short 4100 - http://jnnp.bmj.com/content/early/2017/10/30/jnnp-2017-316003.full AB - Epilepsy is a common neurological disorder occurring in 3% of the US adult population. It is characterised by seizures resulting from aberrant hypersynchronous neural activity. Approximately one-third of newly diagnosed epilepsy cases fail to become seizure-free in response to antiseizure drugs. Optimal seizure control, in cases of drug-resistant epilepsy, often requires neurosurgical intervention targeting seizure foci, such as the temporal lobe. Advances in minimally invasive ablative surgical approaches have led to the development of MRI-guided laser interstitial thermal therapy (LITT). For refractory epilepsy, this surgical intervention offers many advantages over traditional approaches, including real-time lesion monitoring, reduced morbidity, and in some reports increased preservation of cognitive and language processes. We review the use of LITT for epileptic indications in the context of its application as a curative (seizure freedom) or palliative (seizure reduction) measure for both lesional and non-lesional forms of epilepsy. Furthermore, we address the use of LITT for a variety of extratemporal lobe epilepsies. Finally, we describe clinical outcomes, limitations and future applications of LITT for epilepsy.